ClinicalTrials.gg
CompletedNCT00835952ATX-101-08-10Updated Jan 27, 2010

ATX-101 Abdominoplasty

A Phase 1 interventional study of ATX-101 in Characteristics of Subcutaneous Fat, sponsored by Kythera Biopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-01-27.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty

02

Conditions studied

  • Characteristics of Subcutaneous Fat
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects undergoing planned abdominoplasty

Exclusion criteria

Exclusion Criteria:

  • History of interventions in the abdominal area
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    ATX-101

    Drug: ATX-101

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events, laboratory test results, physical examinations

    Time frame: 1 - 28 days

Secondary outcomes

  1. Histopathology

    Time frame: 1 - 28 Days

07

Study locations

2 sites
  • San Francisco, California, United States
  • Santa Monica, California, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2009
First posted
Feb 4, 2009
Start
Nov 2008
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Last update
Jan 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00835952
First posted
Feb 4, 2009
Start date
Nov 2008
Primary completion
Mar 2009
Completion
Apr 2009
Last update
Jan 27, 2010

Study contacts

Patricia Walker, M.D., Ph.D.
study director · Kythera Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion